Universidad Peruana Cayetano Heredia

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Mostrar el registro sencillo del ítem

dc.contributor.author Ugarte Gil, Manuel Francisco
dc.contributor.author Alarcón, Graciela S.
dc.contributor.author Izadi, Zara
dc.contributor.author Duarte-Garcia, Ali
dc.contributor.author Reategui-Sokolova, Cristina
dc.contributor.author Clarke, Ann Elaine
dc.contributor.author Wise, Leanna
dc.contributor.author Pons-Estel, Guillermo J.
dc.contributor.author Santos, Maria Jose
dc.contributor.author Bernatsky, Sasha
dc.contributor.author Euzebio Ribeiro, Sandra Lucia
dc.contributor.author Al Emadi, Samar
dc.contributor.author Sparks, Jeffrey A.
dc.contributor.author Hsu, Tiffany Y-T
dc.contributor.author Patel, Naomi J.
dc.contributor.author Gilbert, Emily L.
dc.contributor.author Valenzuela-Almada, Maria O.
dc.contributor.author Jonsen, Andreas
dc.contributor.author Landolfi, Gianpiero
dc.contributor.author Fredi, Micaela
dc.contributor.author Goulenok, Tiphaine
dc.contributor.author Devaux, Mathilde
dc.contributor.author Mariette, Xavier
dc.contributor.author Queyrel, Viviane
dc.contributor.author Romao, Vasco C.
dc.contributor.author Sequeira, Graca
dc.contributor.author Hasseli, Rebecca
dc.contributor.author Hoyer, Bimba
dc.contributor.author Voll, Reinhard E.
dc.contributor.author Specker, Christof
dc.contributor.author Baez, Roberto
dc.contributor.author Castro-Coello, Vanessa
dc.contributor.author Ficco, Hernan Maldonado
dc.contributor.author Reis Neto, Edgard Torres
dc.contributor.author Aparecida Ferreira, Gilda Aparecida
dc.contributor.author Andre Monticielo, Odirlei Andre
dc.contributor.author Sirotich, Emily
dc.contributor.author Liew, Jean
dc.contributor.author Hausmann, Jonathan
dc.contributor.author Sufka, Paul
dc.contributor.author Grainger, Rebecca
dc.contributor.author Bhana, Suleman
dc.contributor.author Costello, Wendy
dc.contributor.author Wallace, Zachary S.
dc.contributor.author Jacobsohn, Lindsay
dc.contributor.author Taylor, Tiffany
dc.contributor.author Ja, Clairissa
dc.contributor.author Strangfeld, Anja
dc.contributor.author Mateus, Elsa F.
dc.contributor.author Hyrich, Kimme L.
dc.contributor.author Carmona, Loreto
dc.contributor.author Lawson-Tovey, Saskia
dc.contributor.author Kearsley-Fleet, Lianne
dc.contributor.author Schaefer, Martin
dc.contributor.author Machado, Pedro M.
dc.contributor.author Robinson, Philip C.
dc.contributor.author Gianfrancesco, Milena
dc.contributor.author Yazdany, Jinoos
dc.date.accessioned 2022-03-23T16:54:20Z
dc.date.available 2022-03-23T16:54:20Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/11466
dc.description.abstract Aim: To determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19. Methods: People with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity. Results: A total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1–5 mg/day 1.86, 1.20 to 2.66, 6–9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab. Conclusions: More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes. en_US
dc.language.iso eng
dc.publisher BMJ Publishing Group
dc.relation.ispartofseries Annals of the Rheumatic Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.subject COVID-19 en_US
dc.subject systemic lupus erythematosus en_US
dc.subject COVID-19 Global Rheumatology Alliance en_US
dc.title Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1136/annrheumdis-2021-221636
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.17
dc.relation.issn 1468-2060


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas